Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...

ROCHESTER, Minn. (KTTC) – A Winona industrial supply company provided assistance to a Wisconsin high school student’s science ...

The keen interest from Big Pharma has also excited the stock market. After the Otsuka deal was announced, HBM's share price ...

FDA grants accelerated approval to Regeneron's Lynozyfic for relapsed multiple myeloma after strong results in a Phase 1/2 trial.

While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing ...

Najpierw wprowadzenie podatku akcyzowego na saszetki nikotynowe, potem propozycja przepisów, które zmierzają do wycofania tych produktów z rynku – przedstawiciele środowisk ...

"Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma" was originally created and published by ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires.

The reinstatement of two soccer bribery convictions, President Trump's asylum ban being blocked, FDA's approval of ...

A federal bankruptcy court this week approved the sale of 23andMe to TTAM Research Institute - a new company launched by ...

The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the ...

Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for ...